US-listed pharmaceuticals company Merck to spin off Organon after acquisition
Organon, a women’s healthcare-focused drugs developer about to be spun off from US-listed pharmaceuticals company Merck, has agreed to acquire Alydia Health for up to $240m.
Organon will pay $215m upfront plus a $25m contingent milestone payment. Fifty million dollars of the upfront payment will be paid prior to the spinoff of Organon expected in the second quarter; $165m will be paid by Organon upon the close of the acquisition, and the remainder will be paid by Organon upon achievement…
